SITC 2023 | Modified HSV1 for skin cancer treatment

Diwakar Davar, MD, University of Pittsburgh School of Medicine, Pittsburgh, PA, discusses the use of RP1 in the treatment of transplant-associated skin cancer; due to the immunosuppressants used to avoid rejection, this population is at a huge increased risk and represents an unmet need in clinical care. RP1 is based on a genetically modified HSV1 virus and mediates the direct killing of tumor cells as well as mounting the body’s immune response against other tumors (having both local and global efficacy). ARTACUS (NCT04349436) appears to render RP1 effective and safe, with zero incidence of seroconversion and durable response rates. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.